Dr. Ed Kim from the Levine Cancer Institute reviews the potential advantages and current limitations of blood-based testing for molecular markers using circulating tumor cells and circulating tumor DNA in identifying clinically important mutations.
Blood-Based Mutation Testing_ Circulating Tumor Cells and Tumor DNA [360p]
